Loarce et al. Poor performance of CXR and PFT in diagnosing RA-ILD (compared to HRCT). Message is, if you think they have RA-ILD, you need to do CT. @RheumNow #ACR25 Abstr#1335 https://t.co/eeSTf72mvM

Fragoulis et al. Real world study of bimekizumab demonstrates equal efficacy in IL-17i naive and exposed. @RheumNow #ACR25 Abstr#1439 https://t.co/aCcLgnKvFJ

Gensler et al. Bimekizumab in male and female axSpA patients. Greater benefit in males at week 16, but similar responses at week 52 @RheumNow #ACR25 Abstr#1449 https://t.co/zDYI2zItqT

Getting RA patients into remission: have we plateaued? @MayoClinic data: early and later into the biologic era, and still median time to RA remission is >3y Surely we can aspire to more? Let’s target barriers to implementing better #ACR25 @ElHasbaniG @MyasoedovaElena @RheumNow https://t.co/JLTuL5cIet

Mac Gearailt et al. Depression in axSpA. Depression in 10%. Associated higher disease activity, worse functional status, and increased peripheral manifestations. @RheumNow #ACR25 Abstr#1409 https://t.co/8pnoQiaiQr

Kharouf et al. Effect of handedness on radiographic damage in PsA. Left-handedness associated increased peripheral damage, especially in left hand. Hypothesis that having to use tools designed for right-handedness increases mechanical stress @RheumNow #ACR25 Abstr#1415 https://t.co/gfGQkrYyc8

Pope @Janetbirdope et al. Parenteral (IM and/or IA) superior to oral steroids in early RA. Better discontinuation of steroids with no difference in need for advanced therapies. @RheumNow #ACR25 Abstr#1355 #ACRbest https://t.co/OyvnzEGlLE

In a prespecified exploratory analysis of REGENCY trial data by DrRovin et al, Bet. wks 24 and 76: Obinutuzumab ⬇️ LN flares vs. PBO (HR 0.44; p=0.0074) Pts on Obi had less unfavorable kidney outcomes vs. PBO (HR 0.37; p=0.0039) Addtl tx option for LN #ACR25 @RheumNow Abs1521 https://t.co/N5K9Nzh71E

Simko et al. 6-monthly vs 3-monthly MTX lab monitoring. 3821 patients. Appears to be no difference. Potential for significant cost-savings and reduced burden to patients. @RheumNow #ACR25 Abstr#1370 #ACRbest https://t.co/G3tNQq8qXT

Post-hoc analysis of CARE(Ph2B) Study to assess sustained responses in mSLEDAI-2K vs. PBO x 12mos in pts given Cenerimod Sustained response in Cenerimod Ex-4mg (63.5%) > PBO (50%); HR 1.43 Ongoing research, further data needed. #ACR25 @RheumNow Abs1519 https://t.co/cQbVVIIyxW

Really useful observational study, 305 pts with TAK Out of 205 pts w/subsequent imaging, 72 (35%) w/NEW lesions in previously-unaffected territory Majority of lesions stenotic. Emphasizes importance of regular monitoring #ACR25 @RheumNow Abstr#1631 https://t.co/zoWjH0lEym

Infection data from SELECT-GCA: Glucocorticoids seem to drive overall infectious risk UPA use associated with higher zoster - vaccinate!! @RheumNow #ACR25 Abst# 0895 https://t.co/ueVbFPxG0Q